Islamabad, 12 June: Novavax Inc said on Friday its experimental COVID-19 vaccine showed immune response and protection against the highly contagious coronavirus variant originally identified in South Africa in a clinical trial.
The vaccine, NVX-CoV2373, is being tested in multiple trials but has yet to be authorized for use in any country.
Novavax also said studies in mice and baboons found that a different vaccine specifically targeting. The South African variant now known as Beta produced immune response and protection, and that is expected to conduct further clinical testing of the Beta-focused vaccine in the fall.
The company said testing of blood serum of thirty participants of a mid-stage trial who had received both doses of COVID-19 vaccine NVX-CoV2373 revealed robust antibody responses to the original version of the coronavirus as well against the Alpha variant first found in the UK and the Beta variant.
However, the response against the Beta variant was slightly less, Novavax said.
The European Medicines Agency started a rolling review of the Novavax shot in February. Data from its pivotal U.S. and Mexico trial is expected to be released in the current quarter.
The company said the new data is available on the online preprint server bioRxiv and has been submitted for peer review.
Strawberry originated in Europe in the 18th century. It is a hybrid of two wild strawberry species from North America and Chile.
Strawberries are bright red, juicy, and sweet. These are an excellent source of vitamin C and manganese and also contain decent amounts of folate (vitamin B9) and potassium.
Strawberries are very rich in antioxidants and plant compounds, which may have benefits for heart health and blood sugar control.
Usually consumed raw and fresh, these berries can also be used in a variety of jams, jellies, and desserts.